Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

NCT05577000 | Active Not Recruiting Phase 1 DMC FDA Drug

• 2 other identifiers: 22702NCI-2022-08957
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).

Conditions

Refractory Multiple Myeloma; Relapsed Multiple Myeloma

Keywords

CAR-T Therapies

Outcome Measures

Primary Outcomes (3)

• Proportion of participants with treatment-emergent adverse events (AE) (Dose Escalation)

  Proportion of participants with treatment-emergent adverse events of CAR-T as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0, revised cytokine release syndrome (CRS) grading criteria (for CRS), and American Society of Transplantation and Cellular Therapy (ASTCT) Immune Effector Cell Associated Neurotoxicity (ICANS) Consensus Grading for Adults (for neurotoxicity grading). Analyses will be performed for all participants having received at least one dose of study drug and employ a modified criteria for hematologic adverse events.

  From initiation of study treatment (day 1) to 29 days following CAR-T infusion

• Proportion of participants who experience a dose-limiting toxicity (DLT) (Dose Escalation)

  The DLT evaluable analysis set includes all participants in the dose-finding part of the study who have received the anti-BCMA CAR-T cell product, and who have either experienced a DLT or were followed for the full DLT evaluation period (within 28 days following infusion of CAR-T cells targeting BCMA). The MTD is defined as the dose level immediately below that in which \>=2/6 participants experience a DLT and will be used to determine the recommended Phase 2 dose for future studies.

  From initiation of study treatment (day 1) to 29 days following CAR-T infusion

• Overall Response Rate (ORR) (Dose Expansion)

  Overall response rate includes participants with a demonstrated Stringent Complete Response (sCR), Complete Response (CR), Partial Response (PR), or Very Good Partial Response (VGPR) per International Myeloma Working Group (IMWG) criteria reported as proportion with 90% binomial confidence interval for the expansion cohort including the patients on MTD in the dose escalation cohort.

  Up to 12 months following CAR- T infusion

Secondary Outcomes (9)

• Overall Response Rate (ORR)

  Up to 15 years

• Duration of response

  Up to 12 months following CAR- T infusion

• Progression-free Survival (PFS)

  Up to 15 years

• Overall Survival

  Up to 15 years

• Percentage of participants with minimal residual disease, negative (MRD-)

  Up to 15 years

Study Arms (4)

Dose Escalation (150 x 10^6 CAR + T cells/ infusion)

EXPERIMENTAL

Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the starting dose of 150 x 10\^6 flat dose will then be given on Day 1.

Biological: Manufactured Anti-BCMA CAR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide

Dose Escalation (450 x 10^6 CAR + T cells/ infusion)

EXPERIMENTAL

Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the next highest dose of 450 x 10\^6 flat dose will then be given on Day 1.

Biological: Manufactured Anti-BCMA CAR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide

Dose Escalation (600 x 10^6 CAR + T cells/ infusion)

EXPERIMENTAL

Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the next highest dose of 600 x 10\^6 flat dose will then be given on Day 1.

Biological: Manufactured Anti-BCMA CAR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide

Dose Expansion: Maximum Tolerated Dose (MTD)

EXPERIMENTAL

Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the MTD will then be given on Day 1.

Biological: Manufactured Anti-BCMA CAR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide

Interventions

Manufactured Anti-BCMA CAR-T cells BIOLOGICAL

Given IV

Also known as: Anti-BCMA CAR-T cells

Dose Escalation (150 x 10^6 CAR + T cells/ infusion); Dose Escalation (450 x 10^6 CAR + T cells/ infusion); Dose Escalation (600 x 10^6 CAR + T cells/ infusion); Dose Expansion: Maximum Tolerated Dose (MTD)

Fludarabine DRUG

Given IV

Also known as: Fludara

Dose Escalation (150 x 10^6 CAR + T cells/ infusion); Dose Escalation (450 x 10^6 CAR + T cells/ infusion); Dose Escalation (600 x 10^6 CAR + T cells/ infusion); Dose Expansion: Maximum Tolerated Dose (MTD)

Cyclophosphamide DRUG

Given IV

Also known as: Cytoxan

Dose Escalation (150 x 10^6 CAR + T cells/ infusion); Dose Escalation (450 x 10^6 CAR + T cells/ infusion); Dose Escalation (600 x 10^6 CAR + T cells/ infusion); Dose Expansion: Maximum Tolerated Dose (MTD)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily sign informed consent form.
• \>=18 years of age at the time of signing informed consent.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• Diagnosis of MM with relapsed or refractory disease and have had at least 3 different prior lines of therapy including proteasome inhibitor (PI) (e.g., bortezomib or carfilzomib) immunomodulatory therapy (IMiD) (e.g., lenalidomide or pomalidomide), and anti-CD38 antibody therapy.
• Participants must have measurable disease, including at least one of the criteria below:
• Serum M-protein greater or equal to 0.5 g/dL.
• Urine M-protein greater or equal to 200 mg/24 hours (h).
• Serum free light chain (FLC) assay: involved FLC level of \>= 100 mg/L.
• Adequate organ function, defined as:
• Hemoglobulin \>8 gm/dl (transfusions allowed).
• Platelets \>50,000/microliter (uL) (in the absence of platelet transfusion within 7 days of apheresis, but transfusion permitted prior to lymphodepleting chemotherapy).
• Absolute neutrophil count (ANC) \> 1000/uL in the absence of growth factor support (filgrastim within 7 days or pegfilgrastim within 14 days of apheresis, but growth factor permitted prior to lymphodepleting chemotherapy).
• Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =\< 3 x institutional upper limit of normal (ULN).
• Total bilirubin =\< 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome.
• Serum creatinine clearance (CrCl) \>= 45 mL/min using Cockcroft-Gault formula.

You may not qualify if:

• Autologous transplant within 6 weeks of planned CAR-T cell infusion.
• Active other malignancy, other than non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, or breast). Any fully treated malignancies or indolent, clinically insignificant malignancies can be discussed among the study team to determine eligibility.
• HIV seropositivity.
• Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded).
• Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pulmonary abnormalities, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. NOTE: Women of childbearing potential must have a negative serum or urine pregnancy test.
• Patients with currently symptomatic central nervous system (CNS) pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia, and Parkinson's disease.
• History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.
• Eligibility for Infusion of Investigational Product:
• Hematologic function parameters will not be included as a pre-infusion eligibility criterion (because lymphodepletive chemotherapy is expected to cause pancytopenia).
• Laboratory result abnormalities that are considered not clinically significant by the principal investigator AND are not the result of a demonstrated active infection or an active central nervous system condition.
• Use of anti-multiple myeloma therapy, including systemic corticosteroids within 14 days prior to lymphodepletive chemotherapy.
• Neurologic symptoms suggestive of an active central nervous system condition.

Sponsors & Collaborators

• Thomas Martin, MD: lead
• Actavis Inc.: collaborator
• University of California, Davis: collaborator
• Eugia Pharma Specialities Limited: collaborator

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

Location

MeSH Terms

Conditions

Multiple Myeloma

Interventions

fludarabine; fludarabine phosphate; Cyclophosphamide

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Hydrocarbons; Organic Chemicals; Phosphoramides; Organophosphorus Compounds

Study Officials

• Anupama Kumar, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 8, 2022
• First Posted: October 13, 2022
• Study Start: October 18, 2021
• Primary Completion: November 30, 2025
• Study Completion (Estimated): August 31, 2038
• Last Updated: February 20, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)